EUVIMEDEUVIMED entdecken
Crossref

MicroRNA‐29b attenuates fibrosis in a rat model of Peyronie's disease

Patrícia Candido iD, Ruan Pimenta, Feres Camargo Maluf, Caroline Chiovatto, Poliana Romão, Camila Machado Baldavira, Vitória Ghazarian, Juliana A Camargo, Vanessa R Guimarães, Gabriel A Dos Santos, Iran A Silva, Bruno Nascimento und 7 weitere

Andrology · 2025

DOI: 10.1111/andr.13672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Andrology, 2025. Verfasst von Patrícia Candido und 18 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Laboratory of Medical Investigation (LIM55), Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Penile Induration, MicroRNAs, Penis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: São Paulo Research Foundation, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peyronie's disease is characterized by the formation of fibrotic plaques in the penile tunica albuginea. Effective treatments are limited, warranting the investigation of new promising therapies, such as the application of microRNAs that regulate fibrosis‐related genes.

Objective

We aimed to investigate the therapeutic potential of mimicking microRNA‐29b in a fibrin‐induced rat model of Peyronie's disease. Material/methods The study was designed in two phases. To establish an optimal Peyronie's disease model, rats received either human fibrin and thrombin or saline solutions into the tunica albuginea on days 0 and 5. The animal model validation was done through expression and histopathological analyses, the latest by an experienced uropathologist. After validation, we performed microRNA‐29b treatment on days 14, 21, and 28 of the study. This phase had control (normal saline) and scramble (microRNA scramble) groups. The mid‐penile shaft was removed on day 30 for histological examination and molecular analyses in both study stages.

Results

The control group displayed typical tunica albuginea histologic architecture in the animal model validation. In Peyronie's disease group, the Hematoxylin and eosin and Masson Trichrome staining methods demonstrated an interstitial inflammatory process with concomitant dense fibrotic plaques as well as disarrangement of collagen fibers. Additionally, we found out that reduced microRNA‐29b ( p = 0.05) was associated with significantly increased COL1A1 and transforming growth factor β1 genes and proteins ( p > 0.05) in the Peyronie's disease group. After treatment with mimic microRNA‐29b stimulation, the Hematoxylin & eosin and Masson Trichrome staining revealed a discrete and less dense fibrotic plaque. This result was associated with significantly decreasing expression of COL1A1, COL3A1, and transforming growth factor β1 genes and proteins ( p < 0.05).

Discussion

The fibrin‐induced animal model showed significant histopathological and molecular changes compared to the Control group, suggesting that our model was appropriate. Previous findings have shown that increased expression of microRNA‐29b was associated with decreased pathological fibrosis. In the present study, treatment with microRNA‐29b decreased the gene and protein expression of collagens and transforming growth factor β1. This study reveals the therapeutic potential for Peyronie's disease involving molecular targets.

Conclusion

MicroRNA‐29b application on the rat's tunica albuginea attenuated fibrosis, arising as a novel potential strategy for Peyronie's disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Penile IndurationMicroRNAsPenisAnimalsMaleFibrosisDisease Models, AnimalRatsCollagen Type IRats, Sprague-DawleyTransforming Growth Factor beta1Collagen Type IIICollagen Type I, alpha 1 ChainHumans

Stichwörter der Autor:innen

Peyronie's diseasecollagenextracellular matrixfibrosismicroRNAtransforming growth factor beta 1

Substanzen

MicroRNAsMIRN29 microRNA, ratCollagen Type ITransforming Growth Factor beta1Collagen Type IIICollagen Type I, alpha 1 Chain

Autor:innen und Institutionen

  • Urology Department, Laboratory of Medical Investigation (LIM55), Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil.
  • Moriah Institute of Science and Education (MISE), Hospital Moriah, Sao Paulo, Brazil.
  • Department of Immunology and Immunotherapy and Tisch Cancer Institute, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Urology, University of California San Francisco, San Francisco, California, USA.
  • Centro Universitário São Camilo, Sao Paulo, Brazil.
  • Department of Pathology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil.

ORCID-Profile: Patrícia Candido

Förderung

  • São Paulo Research Foundation
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Candido, P., Pimenta, R., Maluf, F. C., Chiovatto, C., Romão, P., Baldavira, C. M., Ghazarian, V., Camargo, J. A., Guimarães, V. R., Santos, G. A. D., Silva, I. A., Nascimento, B., Hallak, J., Capelozzi, V. L., Srougi, M., Nahas, W. C., Viana, N. I., Leite, K. R., & Reis, S. T. (2025). MicroRNA‐29b attenuates fibrosis in a rat model of Peyronie's disease. Andrology. https://doi.org/10.1111/andr.13672

Vancouver

Candido P, Pimenta R, Maluf FC, Chiovatto C, Romão P, Baldavira CM, et al. MicroRNA‐29b attenuates fibrosis in a rat model of Peyronie's disease. Andrology. 2025. doi:10.1111/andr.13672

BibTeX
@article{Candido2025,
  author = {Candido, Patrícia and Pimenta, Ruan and Maluf, Feres Camargo and Chiovatto, Caroline and Romão, Poliana and Baldavira, Camila Machado and Ghazarian, Vitória and Camargo, Juliana A and Guimarães, Vanessa R and Santos, Gabriel A Dos and Silva, Iran A and Nascimento, Bruno and Hallak, Jorge and Capelozzi, Vera Luiza and Srougi, Miguel and Nahas, William C and Viana, Nayara I and Leite, Katia R and Reis, Sabrina T},
  title = {MicroRNA‐29b attenuates fibrosis in a rat model of Peyronie's disease},
  journal = {Andrology},
  year = {2025},
  doi = {10.1111/andr.13672}
}
Kostenlos starten →